Last reviewed · How we verify
NCT05461365
Intranasal Insulin for COVID-19-related Smell Loss
Phase 3 trial testing Insulin in Anosmia in 27 participants. Completed in 20 December 2021.
25 November 2021
Quick facts
| Lead sponsor | Universidad Panamericana |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 27 |
| Start date | 4 January 2021 |
| Primary completion | 25 November 2021 |
| Estimated completion | 20 December 2021 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Insulin (insulin) — full drug profile →
Conditions studied
- Anosmia — all drugs for Anosmia →
- Smell Loss — all drugs for Smell Loss →
- Paraosmia — all drugs for Paraosmia →
- Hyposmia — all drugs for Hyposmia →
Sponsor
Universidad Panamericana
Who can join
Adults 18 to 59, any sex, with Anosmia or Smell Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to quantify the improvement in olfaction of 27 post-COVID-19 patients, after three intreventions of intranasal insulin during a four week period, with the help of the Threshold, Discrimination and Identification (TDI) score evaluated with Sniffin Sticks®.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Post-COVID-19 Anosmia and Therapies: Stay Tuned for New Drugs to Sniff Out.
Riccardi G, Niccolini GF, Bellizzi MG, Fiore M, et al · · 2023 · cited 11× · PMID 37366867 · DOI 10.3390/diseases11020079
Verify or expand the search:
- PubMed search for NCT05461365
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Insulin
Trials testing the same drug.
- NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
- NCT07259564 — A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) · Phase 2 · not yet recruiting
- NCT06762314 — Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes · Phase 2 · recruiting
- NCT06781775 — GDM: Insulin with or Without Metformin? · Phase 4 · recruiting
- NCT06391853 — Investigating Brain Insulin Resistance in Alzheimer Disease with IntraNasal Insulin : a Multimodal Neuroimaging Study · NA · withdrawn
Other recruiting trials for Anosmia
Currently open trials in the same condition.
- NCT06733636 — Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults · NA · recruiting
- NCT05562050 — Characteristics of the Anosmic Olfactory Mucosa · active not recruiting
- NCT05040659 — Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2 · active not recruiting
- NCT05364125 — Olfactory Training on Smell Dysfunction Patients in HK · NA · recruiting
- NCT06423495 — Efficacy of Photobiomodulation in the Rehabilitation of Olfactory Dysfunctions Induced by Long COVID-19 · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05461365 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Panamericana
- Last refreshed: 18 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05461365.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing